Biomedical Refrigerator and Freezer Market Report 2026

The biomedical refrigerator and freezer market size has grown rapidly in recent years. It will grow from $4.34 billion in 2025 to $4.8 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing demand for vaccine storage during global immunization programs, rising need for reliable blood and plasma storage in hospitals, growth of pharmaceutical research requiring controlled temperature storage, expansion of clinical laboratories and diagnostic infrastructure, development of early cold chain logistics systems for healthcare supply chains.

The biomedical refrigerator and freezer market size is expected to see rapid growth in the next few years. It will grow to $7.25 billion by 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to rising demand for biologics and cell based therapies requiring ultra low temperature storage, increasing focus on vaccine distribution and pandemic preparedness infrastructure, growing adoption of smart monitoring and connected refrigeration systems, expansion of biobanking and genomic research requiring long term sample preservation, increasing regulatory standards for temperature sensitive medical storage. Major trends in the forecast period include IoMT enabled biomedical refrigeration systems with real time temperature monitoring and predictive alerts, energy efficient ultra low temperature freezer designs reducing operational carbon footprint, cloud based cold chain monitoring platforms for vaccine and biologics storage management, automated inventory and sample tracking integration in biomedical storage systems, advanced insulation and cryogenic cooling technologies for extended biological preservation.

The increasing clinical trial activities are expected to propel the growth of the biomedical refrigerator and freezer market going forward. Clinical trial activities encompass the planning, conduct, monitoring, and analysis of research studies aimed at evaluating the safety, efficacy, and outcomes of medical interventions in human participants. The rising clinical trial activities are being driven by the growing demand for innovative therapies, as pharmaceutical and biotechnology companies are increasingly undertaking studies to develop new drugs and treatments that address unmet medical needs across global markets. The expansion of clinical trials is contributing to a higher requirement for biomedical refrigerators and freezers, as a growing volume of biological samples, vaccines, and experimental drugs must be maintained under strict controlled temperature conditions to preserve their safety, stability, and effectiveness. For instance, in March 2026, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, the UK recorded a 36% increase in the number of commercial clinical trials launched in 2024 compared to the previous year, advancing two positions to rank sixth globally in competitiveness for all Phase III trials initiated during that year. Therefore, the increasing clinical trial activities are significantly propelling the growth of the biomedical refrigerator and freezer market.

Leading companies operating in the biomedical refrigerators and freezers market are focusing on developing advanced solutions, such as ultra-low temperature (ULT) freezers, to enhance sample preservation, improve workflow efficiency, and support regulatory compliance in laboratory and clinical settings. Ultra-low temperature (ULT) freezers refer to refrigeration systems capable of maintaining extremely low temperatures (typically -40°C to -86°C) for the storage of biological materials, pharmaceuticals, and cell- and gene-therapy products. For example, in April 2024, Thermo Fisher Scientific Inc., a US-based life sciences technology company, launched the TSX Universal Series ULT Freezers. Designed to assist scientists across diverse workflows, the freezers feature Universal V-Drive technology, tighter temperature control, faster recovery times, and universal voltage support, while achieving ISO Class 5.5 cleanroom compliance. These enhancements enable reliable long-term storage of blood, blood products, and sensitive biological materials in academic, GMP, and research laboratories, while improving energy efficiency and supporting sustainability goals.

In December 2025, AddLife AB, a Sweden-based life science and laboratory technology company, acquired Pharmacold A/S for an undisclosed amount. Through this acquisition, AddLife intends to expand its biomedical refrigeration and cold storage offerings, enhancing its service capabilities and providing advanced, temperature-controlled solutions for the pharmaceutical, healthcare, and research sectors. Pharmacold A/S is a Denmark-based company that designs, installs, and services customized refrigeration and freezer systems for pharmaceutical and healthcare applications.

Major companies operating in the biomedical refrigerator and freezer market are Thermo Fisher Scientific Inc., Liebherr Group, Follett LLC, Dometic Group, PHC Holdings Corporation, Eppendorf AG, Telstar SA, Binder GmbH, B Medical Systems S. à r. l., Helmer Inc., Vestfrost Solutions, Arctiko A/S, Jeio Tech Inc., So-Low Environmental Equipment Co. Inc., Migali Industries Inc., Desmon S. p. A., Labcold Ltd., Philipp Kirsch GmbH, Gram Commercial A/S, Haier Biomedical International, Fiocchetti Scientific S. r. l., Evermed S. r. l., Accucold, Froilabo.

North America was the largest region in the biomedical refrigerator and freezer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomedical refrigerator and freezer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biomedical refrigerator and freezer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biomedical refrigerator and freezer market consists of sales of CO₂ incubator-compatible refrigerators, ice-lined refrigerators, portable biomedical freezers, and alarmed refrigerators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.